MML Investors Services LLC Boosts Stock Holdings in Cencora, Inc. (NYSE:COR)

MML Investors Services LLC raised its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,852 shares of the company's stock after acquiring an additional 2,402 shares during the period. MML Investors Services LLC's holdings in Cencora were worth $19,739,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of COR. Passumpsic Savings Bank increased its position in Cencora by 4.9% during the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock valued at $1,455,000 after acquiring an additional 304 shares during the last quarter. Virtu Financial LLC increased its position in Cencora by 112.2% during the third quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock valued at $2,302,000 after acquiring an additional 5,407 shares during the last quarter. World Investment Advisors LLC bought a new position in Cencora during the third quarter valued at $4,072,000. Arvest Bank Trust Division bought a new position in shares of Cencora in the third quarter worth about $218,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Cencora in the 3rd quarter worth about $566,000. Institutional investors own 97.52% of the company's stock.

Analyst Upgrades and Downgrades

COR has been the topic of a number of research analyst reports. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and a consensus target price of $284.55.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. 10.80% of the stock is owned by insiders.

Cencora Stock Performance

Shares of COR traded up $3.66 during trading hours on Friday, reaching $286.05. 1,815,757 shares of the company traded hands, compared to its average volume of 1,522,859. The stock has a market capitalization of $55.47 billion, a P/E ratio of 40.69, a P/E/G ratio of 1.31 and a beta of 0.55. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $296.65. The business has a fifty day moving average price of $268.09 and a 200-day moving average price of $249.54.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.77%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.